Image: genomic biomarkers can help to predict the efficacy and safety of specific treatments in individuals (Photo courtesy of Qiagen).
A broad collaboration agreement between two companies will allow the development and commercialization of companion diagnostics. Financial terms of the agreement are not disclosed.
Qiagen (Hilden, Germany) companion diagnostics is collaborating with Lilly medicines (Indianapolis, IN, USA) in an effort to improve outcomes for individual patients.
Companion diagnostics discover a patient’s molecular information in order to guide treatment decisions for specific cancers or other diseases. The agreement builds on Qiagen and Lilly’s past work together. It provides a framework for Lilly and Qiagen to collaborate on future projects, across all of Lilly’s therapeutic areas, aimed at bringing to market Lilly medicines paired with Qiagen diagnostics.
“Tailored therapies are a key component of Lilly’s strategy of providing improved outcomes for individual patients. By working with partners like Qiagen, we are advancing a number of tailored therapeutics in an effort to target the right medicine to the right patient,” said Daniel Skovronsky, MD, PhD, vice president, tailored therapeutics, Lilly, and CEO, Avid Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. “This collaboration with Qiagen extends our capabilities to more quickly and cost-effectively bring innovative new medicines, alongside advanced diagnostics, to patients worldwide who are waiting.”
Qiagen and Lilly have previously collaborated on companion diagnostics designed to run on Qiagen's Rotor-Gene Q system, a component of the QIAsymphony family of automated instruments, which is revolutionizing laboratory workflows. Qiagen's strategy is to develop US Food and Drug Administration (FDA; Silver Spring, MD, USA) approved diagnostics in the United States for use on this platform.
US Food and Drug Administration